glp-1 drugs in development Trends the of Receptor Agonists The GLP-1 Agonists and Obesity:

Human Molecular Genetics, 2006, Vol

It is an opportunity to support your health and wellness with targeted, nutrient-rich treatments

If your insurance doesnt cover GLP-1s, or if you dont have insurance, there are discounted options available through the pharmaceutical companies that manufacture the medications

O'Connor et al., 2015

Biopharma companies with GLP-1 (glucagon-like peptide-1) analogs, which have become a new trend in the obesity treatment market long dominated by appetite suppressants and fat-absorbance inhibitors, are upgrading their treatments

However, you dont have to be diabetic to have some level of insulin resistance